Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 19/20 | 1.00 |
| ▸ | HTR2C | P28335 | 14/20 | 1.00 |
| ▸ | HTR3A | P46098 | 8/20 | 0.72 |
| ▸ | HTR1D | P28221 | 9/20 | 0.68 |
| ▸ | HTR2A | P28223 | 6/20 | 0.61 |
| ▸ | HTR6 | P50406 | 2/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | HTR5A | P47898 | 2/20 | 0.52 |
| ▸ | HTR1B | P28222 | 2/20 | 0.47 |
| ▸ | HTR1E | P28566 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pulicatin A SCHEMBL15412524 | 1.00 | HTR2B (1.00) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| Pulicatin A SCHEMBL12469056 | 1.00 | HTR2B (1.00) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| Pulicatin A SCHEMBL15412607 | 1.00 | HTR2B (1.00) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| Pulicatin A SCHEMBL19307974 | 1.00 | HTR2B (1.00) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| SCHEMBL12469329 | 0.74 | HTR2B (0.58) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| SCHEMBL3305343 | 0.68 | HTR2B (0.51) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| Aerugine SCHEMBL12468918 | 0.67 | HTR2B (1.00) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| Aerugine SCHEMBL12468920 | 0.67 | HTR2B (1.00) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| Aerugine SCHEMBL29926829 | 0.67 | HTR2B (1.00) | HTR2BHTR2CHTR3AHTR1DHTR2A | |
| SCHEMBL19307988 | 0.66 | HTR2B (0.62) | HTR2BHTR2CHTR3AHTR1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751847-B2 | Methods and compositions related to neuroactive thiazoline compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751847-B2 | Methods and compositions related to neuroactive thiazoline compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | TACR2, TACR3, TACR1 | HTR2B 58/4885HTR2C 9/4885HTR3A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.